Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.